Xenon reported no revenue and a net loss of $90.9 million in Q3 2025, reflecting increased investment in late-stage trials. Cash and marketable securities totaled $555.3 million. The company expects to be funded into 2027.

Xenon Pharmaceuticals reported a net loss of $84.7 million for Q2 2025, an increase from $57.9 million in Q2 2024, primarily due to higher research and development expenses driven by the azetukalner program. The company completed patient recruitment for its Phase 3 X-TOLE2 study, with topline data expected in early 2026, and initiated new Phase 3 studies for azetukalner in MDD and BPD. Cash and cash equivalents stood at $624.8 million, providing sufficient funding into 2027.

Xenon Pharmaceuticals reported a net loss of $65.7 million for Q4 2024, an increase from $44.7 million in Q4 2023, primarily due to higher research and development expenses. The company anticipates having sufficient cash to fund operations into 2027.

Xenon Pharmaceuticals reported a net loss of $62.8 million for the quarter ended September 30, 2024, compared to a net loss of $48.5 million for the same period in 2023. As of September 30, 2024, cash and cash equivalents and marketable securities were $803.3 million.

Xenon Pharmaceuticals reported a net loss of $57.9 million for the quarter ended June 30, 2024, compared to a net loss of $47.5 million for the same period in 2023. The company's cash and cash equivalents and marketable securities were $850.6 million as of June 30, 2024.

Xenon Pharmaceuticals reported a net loss of $47.9 million for the first quarter of 2024, compared to a net loss of $41.7 million for the same period in 2023. As of March 31, 2024, cash and cash equivalents and marketable securities were $885.4 million.

Xenon Pharmaceuticals reported a net loss of $44.7 million for the fourth quarter of 2023. The company's cash and cash equivalents and marketable securities were $930.9 million as of December 31, 2023, expected to fund operations into 2027. The company is advancing its XEN1101 program in epilepsy and major depressive disorder.

Xenon Pharmaceuticals reported no revenue for the third quarter of 2023. Research and development expenses increased to $42.9 million, and general and administrative expenses rose to $12.8 million. The net loss for the quarter was $48.5 million. Cash and cash equivalents and marketable securities totaled $639.1 million as of September 30, 2023.

Xenon Pharmaceuticals reported first quarter 2023 financial results with no revenue recognized compared to $8.8 million for the same period in 2022. Research and development expenses were $39.5 million, and general and administrative expenses were $9.5 million. The net loss for the quarter was $41.7 million. Cash and cash equivalents and marketable securities were $687.3 million as of March 31, 2023.

Xenon Pharmaceuticals reported no revenue for the fourth quarter of 2022. Research and development expenses were $34.8 million, and general and administrative expenses were $8.5 million, resulting in a net loss of $37.4 million. Cash and cash equivalents and marketable securities were $720.8 million as of December 31, 2022.

Xenon Pharmaceuticals reported a net loss of $37.2 million for the third quarter of 2022, compared to a net loss of $15.4 million for the same period in 2021. The company's cash and cash equivalents and marketable securities were $752.2 million as of September 30, 2022, providing a cash runway into 2026.

Xenon Pharmaceuticals reported a net loss of $31.2 million for the second quarter of 2022, with revenue of $0.5 million. The company's cash and cash equivalents and marketable securities totaled $788.2 million, expected to fund operations into 2026. Key clinical programs, including XEN1101 for epilepsy and major depressive disorder, are advancing, with Phase 3 trials planned or underway.